Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.

Background and Objectives: Breast cancer is the most common malignant neoplasm worldwide and the most prevalent one among women. It represents the leading cause of cancer-related death among females. Cyclin-dependent kinase 4 and 6 inhibitors disrupt the cell cycle, inducing cellular senescence and,...

Descripción completa

Detalles Bibliográficos
Autores: Santander Ballestín, Sonia, Abadía Labena, María, Avedillo-Salas, Ana, Marco Continente, Cristina, Arribas Blázquez, Marina, Luesma Bartolomé, María José
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/118832
Acceso en línea:https://hdl.handle.net/20.500.14352/118832
Access Level:acceso abierto
Palabra clave:Breast cancer
Cyclin-dependent kinase 4 and 6 inhibitors
Endocrine therapy
Hormone therapy
Metastasis
Medicina
3209 Farmacología
id ES_60fa3232bec3727771ebcb3103d2da91
oai_identifier_str oai:docta.ucm.es:20.500.14352/118832
network_acronym_str ES
network_name_str España
repository_id_str
spelling Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.Santander Ballestín, SoniaAbadía Labena, MaríaAvedillo-Salas, AnaMarco Continente, CristinaArribas Blázquez, MarinaLuesma Bartolomé, María JoséBreast cancerCyclin-dependent kinase 4 and 6 inhibitorsEndocrine therapyHormone therapyMetastasisMedicina3209 FarmacologíaBackground and Objectives: Breast cancer is the most common malignant neoplasm worldwide and the most prevalent one among women. It represents the leading cause of cancer-related death among females. Cyclin-dependent kinase 4 and 6 inhibitors disrupt the cell cycle, inducing cellular senescence and, ultimately, apoptosis. Consequently, they have become a novel type of adjuvant therapy for the treatment of advanced or metastatic breast cancer characterised by positive hormone receptors and human epidermal growth factor receptor 2 (HER-2) negative. Methods: A systematic review was conducted, analysing the available literature on cyclin-dependent kinase 4 and 6 inhibitors published over the last five years. The aim was to evaluate the efficacy and safety of adding these drugs to the standard endocrine therapy for this pathology. Results: The combination of cyclin-dependent kinase 4 and 6 inhibitors with endocrine therapy was shown to improve progression-free survival, overall survival, and chemotherapy-free intervals in patients who received this combination therapy. Conclusions: The addition of CDK4/6 inhibitors to endocrine therapy in the treatment of advanced or metastatic breast cancer with positive hormone receptors and HER-2 negative significantly improved PFS, median survival, and chemotherapy-free intervals compared with the use of hormonal treatments alone or in combination with a placebo. Currently, CDK4/6 inhibitors are becoming established as a new standard treatment for this pathology, offering lower toxicity than chemotherapy. However, it is necessary to deeply investigate the mechanisms of treatment resistance and develop effective therapies to overcome them.MDPIUniversidad Complutense de Madrid20252025-02-2420252025-02-24journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/118832reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1188322026-06-02T12:44:21Z
dc.title.none.fl_str_mv Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
title Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
spellingShingle Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
Santander Ballestín, Sonia
Breast cancer
Cyclin-dependent kinase 4 and 6 inhibitors
Endocrine therapy
Hormone therapy
Metastasis
Medicina
3209 Farmacología
title_short Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
title_full Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
title_fullStr Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
title_full_unstemmed Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
title_sort Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment.
dc.creator.none.fl_str_mv Santander Ballestín, Sonia
Abadía Labena, María
Avedillo-Salas, Ana
Marco Continente, Cristina
Arribas Blázquez, Marina
Luesma Bartolomé, María José
author Santander Ballestín, Sonia
author_facet Santander Ballestín, Sonia
Abadía Labena, María
Avedillo-Salas, Ana
Marco Continente, Cristina
Arribas Blázquez, Marina
Luesma Bartolomé, María José
author_role author
author2 Abadía Labena, María
Avedillo-Salas, Ana
Marco Continente, Cristina
Arribas Blázquez, Marina
Luesma Bartolomé, María José
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv Breast cancer
Cyclin-dependent kinase 4 and 6 inhibitors
Endocrine therapy
Hormone therapy
Metastasis
Medicina
3209 Farmacología
topic Breast cancer
Cyclin-dependent kinase 4 and 6 inhibitors
Endocrine therapy
Hormone therapy
Metastasis
Medicina
3209 Farmacología
description Background and Objectives: Breast cancer is the most common malignant neoplasm worldwide and the most prevalent one among women. It represents the leading cause of cancer-related death among females. Cyclin-dependent kinase 4 and 6 inhibitors disrupt the cell cycle, inducing cellular senescence and, ultimately, apoptosis. Consequently, they have become a novel type of adjuvant therapy for the treatment of advanced or metastatic breast cancer characterised by positive hormone receptors and human epidermal growth factor receptor 2 (HER-2) negative. Methods: A systematic review was conducted, analysing the available literature on cyclin-dependent kinase 4 and 6 inhibitors published over the last five years. The aim was to evaluate the efficacy and safety of adding these drugs to the standard endocrine therapy for this pathology. Results: The combination of cyclin-dependent kinase 4 and 6 inhibitors with endocrine therapy was shown to improve progression-free survival, overall survival, and chemotherapy-free intervals in patients who received this combination therapy. Conclusions: The addition of CDK4/6 inhibitors to endocrine therapy in the treatment of advanced or metastatic breast cancer with positive hormone receptors and HER-2 negative significantly improved PFS, median survival, and chemotherapy-free intervals compared with the use of hormonal treatments alone or in combination with a placebo. Currently, CDK4/6 inhibitors are becoming established as a new standard treatment for this pathology, offering lower toxicity than chemotherapy. However, it is necessary to deeply investigate the mechanisms of treatment resistance and develop effective therapies to overcome them.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-02-24
2025
2025-02-24
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/118832
url https://hdl.handle.net/20.500.14352/118832
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409358772699136
score 15,81155

Similares en LA Referencia